Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 14/20 | 0.72 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.53 |
| ▸ | CDC42BPB | Q9Y5S2 | 4/20 | 0.53 |
| ▸ | CDC42BPA | Q5VT25 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28049906 | 0.81 | LRRK2 (0.79) | LRRK2HSP90AB1ROCK2ROCK1CDC42BPB | |
| SCHEMBL16178118 | 0.81 | LRRK2 (1.00) | LRRK2HSP90AB1ROCK2ROCK1CDC42BPB | |
| SCHEMBL2562516 | 0.81 | HSP90AB1 (1.00) | LRRK2HSP90AB1ROCK2ROCK1CDC42BPB | |
| SCHEMBL13543854 | 0.80 | HSP90AB1 (0.45) | LRRK2HSP90AB1ROCK2ROCK1CDC42BPB | |
| SCHEMBL14260172 | 0.80 | HSP90AB1 (0.48) | LRRK2HSP90AB1ROCK2ROCK1CDC42BPB | |
| SCHEMBL16190651 | 0.78 | LRRK2 (0.67) | LRRK2HSP90AB1ROCK2ROCK1CDC42BPB | |
| SCHEMBL3566122 | 0.76 | HSP90AB1 (0.43) | LRRK2HSP90AB1ROCK2ROCK1CDC42BPB | |
| SCHEMBL3565489 | 0.76 | LRRK2 (0.72) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL3571954 | 0.73 | HSP90AB1 (0.40) | LRRK2HSP90AB1ROCK2ROCK1CDC42BPB | |
| SCHEMBL2568064 | 0.73 | HSP90AB1 (0.71) | LRRK2HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2986608-B1 | ARYLPYRROLOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H LUNDBECK AS (DK) | 2017-08-23 | — | — | EP | claimed |
| EP-2986608-A1 | ARYLPYRROLOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H. Lundbeck A/S (DK) | 2016-02-24 | — | — | EP | claimed |
| WO-2014170248-A1 | ARYLPYRROLOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2014-10-23 | — | — | WO | claimed |
| US-20140315901-A1 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2014-10-23 | — | — | US | claimed |
| US-20100010037-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | VERNALIS (R&D) LTD. (GB) | 2010-01-14 | — | — | US | claimed |
| EP-2986608-B1 | ARYLPYRROLOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H LUNDBECK AS (DK) | 2017-08-23 | — | — | EP | disclosed |
| US-9675594-B2 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2017-06-13 | — | — | US | disclosed |
| US-20170020850-A1 | Arylpyrrolopyridine Derived Compounds as LRRK2 Inhibitors | H. Lundebck A/S (DK) | 2017-01-26 | — | — | US | disclosed |
| US-9499542-B2 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-11-22 | — | — | US | disclosed |
| US-20160102089-A1 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-04-14 | — | — | US | disclosed |
| EP-2986608-A1 | ARYLPYRROLOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H. Lundbeck A/S (DK) | 2016-02-24 | — | — | EP | disclosed |
| WO-2014170248-A1 | ARYLPYRROLOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2014-10-23 | — | — | WO | disclosed |
| US-20140315901-A1 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2014-10-23 | — | — | US | disclosed |
| US-20100010037-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | VERNALIS (R&D) LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010037-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | VERNALIS (R&D) LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010037-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | VERNALIS (R&D) LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| EP-2057155-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | Vernalis (R&D) Limited (GB) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008025947-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | VERNALIS (R & D) LTD. (GB) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008025947-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | VERNALIS (R & D) LTD. (GB) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020850-A1 | Arylpyrrolopyridine Derived Compounds as LRRK2 Inhibitors | LRRK2, PARK7, SNCA | LRRK2 1/4885HSP90AB1 1027/4885ROCK2 1125/4885 |
| US-20100010037-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | LRRK2 2502/4885HSP90AB1 1/4885ROCK2 294/4885 |
| US-20160102089-A1 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | LRRK2, PARK7, SNCA | LRRK2 1/4885HSP90AB1 779/4885ROCK2 1357/4885 |
| US-20140315901-A1 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | LRRK2, PARK7, SNCA | LRRK2 1/4885HSP90AB1 1097/4885ROCK2 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.